These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 3440224)
1. Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. Horton J; Knuiman M; Keller AM; Vogel H; Gale KE; Hahn RG; Rosenbluth RJ; Tormey DC Cancer; 1987 Nov; 60(9):2137-40. PubMed ID: 3440224 [TBL] [Abstract][Full Text] [Related]
2. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. Russell CA; Green SJ; O'Sullivan J; Hynes HE; Budd GT; Congdon JE; Martino S; Osborne CK J Clin Oncol; 1997 Jul; 15(7):2494-501. PubMed ID: 9215817 [TBL] [Abstract][Full Text] [Related]
3. Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and/or aminoglutethimide. Brufman G; Isacson R; Haim N; Gez E; Sulkes A Oncology; 1994; 51(3):258-61. PubMed ID: 8196908 [TBL] [Abstract][Full Text] [Related]
4. A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study. Grem JL; Falkson G; Love RR; Tormey DC Am J Clin Oncol; 1988 Oct; 11(5):528-34. PubMed ID: 3177253 [TBL] [Abstract][Full Text] [Related]
5. Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. Hardy JR; Powles TJ; Judson IR; Sinnett HD; Ashley SE; Coombes RC; Ellin CL Eur J Cancer; 1990; 26(7):824-7. PubMed ID: 2145904 [TBL] [Abstract][Full Text] [Related]
6. A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer. A Study of the Eastern Cooperative Oncology Group (E2185). Cobau CD; Declercq K; Neuberg D; Ingle JN; Tormey DC Cancer; 1996 Feb; 77(3):483-9. PubMed ID: 8630955 [TBL] [Abstract][Full Text] [Related]
7. High-dose megestrol acetate as third-line endocrine therapy for metastatic breast cancer. Cruz JM; Muss HB; Russell G Oncology; 1992; 49 Suppl 2():8-11. PubMed ID: 1461630 [TBL] [Abstract][Full Text] [Related]
8. Megestrol acetate: phase II study of a single daily administration in advanced breast cancer. Pronzato P; Brema F; Amoroso D; Bertelli G; Conte PF; Martini MC; Pastorino G; Rosso R Breast Cancer Res Treat; 1990 Nov; 17(1):51-4. PubMed ID: 2095927 [TBL] [Abstract][Full Text] [Related]
9. Endocrine effects of the combination of megestrol acetate and tamoxifen in the treatment of metastatic breast cancer. Alexieva-Figusch J; Blankenstein MA; de Jong FH; Lamberts SW Eur J Cancer Clin Oncol; 1984 Sep; 20(9):135-40. PubMed ID: 6434315 [TBL] [Abstract][Full Text] [Related]
10. High-dose megestrol acetate for the treatment of advanced breast cancer: dose and toxicities. Aisner J; Tchekmedyian NS; Moody M; Tait N Semin Hematol; 1987 Apr; 24(2 Suppl 1):48-55. PubMed ID: 3589708 [TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Gill PG; Gebski V; Snyder R; Burns I; Levi J; Byrne M; Coates A Ann Oncol; 1993 Nov; 4(9):741-4. PubMed ID: 8280654 [TBL] [Abstract][Full Text] [Related]
12. Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate. Hoffman MS; Roberts WS; Cavanagh D; Praphat H; Solomon P; Lyman GH Gynecol Oncol; 1989 Oct; 35(1):75-7. PubMed ID: 2477317 [TBL] [Abstract][Full Text] [Related]
13. Cyclic sequential endocrine therapy for advanced breast cancer using a combination of tamoxifen and megestrol acetate. Crawford DJ; George WD; Smith DC; Stewart M; Paul J; Leake RE Oncology; 1994 Oct; 51 Suppl 1():13-8. PubMed ID: 7970503 [TBL] [Abstract][Full Text] [Related]
14. Megestrol acetate in advanced breast carcinoma. Espie M Oncology; 1994 Oct; 51 Suppl 1():8-12. PubMed ID: 7970508 [TBL] [Abstract][Full Text] [Related]
15. High-dose megestrol acetate in the treatment of advanced breast cancer. Tchekmedyian NS; Tait N; Abrams J; Aisner J Semin Oncol; 1988 Apr; 15(2 Suppl 1):44-9. PubMed ID: 3368800 [TBL] [Abstract][Full Text] [Related]
16. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Pandya KJ; Yeap BY; Weiner LM; Krook JE; Erban JK; Schinella RA; Davis TE Am J Clin Oncol; 2001 Feb; 24(1):43-6. PubMed ID: 11232948 [TBL] [Abstract][Full Text] [Related]
17. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Lundgren S; Gundersen S; Klepp R; Lønning PE; Lund E; Kvinnsland S Breast Cancer Res Treat; 1989 Nov; 14(2):201-6. PubMed ID: 2690972 [TBL] [Abstract][Full Text] [Related]
18. Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy. Cruz JM; Muss HB; Brockschmidt JK; Evans GW Semin Oncol; 1990 Dec; 17(6 Suppl 9):63-7. PubMed ID: 2259928 [TBL] [Abstract][Full Text] [Related]
19. Megestrol acetate: first-line therapy for advanced breast cancer. Johnson PA; Bonomi PD; Anderson KM; Wolter JM; Economou SG Semin Oncol; 1986 Dec; 13(4 Suppl 4):15-9. PubMed ID: 3798124 [TBL] [Abstract][Full Text] [Related]
20. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]